Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory
NESS ZIONA, Israel, Sept. 28, 2022 /PRNewswire/ — Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing treatments for ALS and diabetes, has been granted its third patent approval for the company’s innovative cell selection and enrichment technology and its use in the production of IsletRx, the company’s treatment and potential cure for diabetes. […]